The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over

Miro Health

Status: Enrolling

Conditions: Mild Cognitive Impairment; Depression

Study type: Observational

Funder types: Other

Identifiers

NCT06011681

MH202206MCILLD

Details and patient eligibility

About

Mild cognitive impairment (MCI) leading to Alzheimer's disease and related disorders (ADRD) represents a significant health and economic burden of the rapidly expanding senior population. The accurate detection and diagnosis of MCI and its common comorbidity, late-life depression (LLD), is essential for prolonging patient quality of life and developing advancements in research and treatment options. The purpose of the proposed program is to refine Miro Health's A.I. to accurately detect, differentiate and diagnose MCI and LLD.

Enrollment: 960 estimated patients

Sex: All

Ages: 60+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• LLD: Age 60 or over; diagnosis of LLD or symptoms consonant with LLD; PHQ-9 score from 15 to 27
• MCI: Age 60 or over; diagnosis of MCI or self-reported insidious onset and continued worsening of cognitive decline; intact activities of daily living
• HC: Age 60 or over

Exclusion criteria

• Age 59 or younger; history of unresolved neurological or psychiatric conditions; current medications known to affect cognition; history of substance abuse; unable to perform activities of daily living; change in employment status due to condition

Trial design

960 participants in 3 patient groups

Depression

Description:

Seniors diagnosed with late life depression or with a concern of late life depression.

Mild cognitive impairment

Description:

Seniors with self-reported decline in cognitive function or with a diagnosis of mild cognitive impairment.

Healthy controls

Description:

Seniors with no neurological or psychiatric symptoms or conditions.